Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2012

Open Access 01-12-2012 | Research article

Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects

Authors: Reinier P Akkermans, Marvin A Berrevoets, Ivo J Smeele, Annelies E Lucas, Bart P Thoonen, Joke G Grootens-Stekelenburg, Yvonne F Heijdra, Chris van Weel, Tjard R Schermer

Published in: BMC Pulmonary Medicine | Issue 1/2012

Login to get access

Abstract

Background

Current COPD guidelines advocate a fixed < 0.70 FEV1/FVC cutpoint to define airflow obstruction. We compared rate of lung function decline in respiratory symptomatic 40+ subjects who were 'obstructive' or 'non-obstructive' according to the fixed and/or age and gender specific lower limit of normal (LLN) FEV1/FVC cutpoints.

Methods

We studied 3,324 respiratory symptomatic subjects referred to primary care diagnostic centres for spirometry. The cohort was subdivided into four categories based on presence or absence of obstruction according to the fixed and LLN FEV1/FVC cutpoints. Postbronchodilator FEV1 decline served as primary outcome to compare subjects between the respective categories.

Results

918 subjects were obstructive according to the fixed FEV1/FVC cutpoint; 389 (42%) of them were non-obstructive according to the LLN cutpoint. In smokers, postbronchodilator FEV1 decline was 21 (SE 3) ml/year in those non-obstructive according to both cutpoints, 21 (7) ml/year in those obstructive according to the fixed but not according to the LLN cutpoint, and 50 (5) ml/year in those obstructive according to both cutpoints (p = 0.004).

Conclusion

This study showed that respiratory symptomatic 40+ smokers and non-smokers who show FEV1/FVC values below the fixed 0.70 cutpoint but above their age/gender specific LLN value did not show accelerated FEV1 decline, in contrast with those showing FEV1/FVC values below their LLN cutpoint.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176 (6): 532-555. 10.1164/rccm.200703-456SO.CrossRefPubMed Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176 (6): 532-555. 10.1164/rccm.200703-456SO.CrossRefPubMed
2.
go back to reference Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007, 370 (9589): 741-750. 10.1016/S0140-6736(07)61377-4.CrossRefPubMed Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007, 370 (9589): 741-750. 10.1016/S0140-6736(07)61377-4.CrossRefPubMed
3.
go back to reference Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al: The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006, 27 (3): 627-643. 10.1183/09031936.06.00024605.CrossRefPubMed Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al: The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006, 27 (3): 627-643. 10.1183/09031936.06.00024605.CrossRefPubMed
5.
go back to reference Janssens JP, Pache JC, Nicod LP: Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999, 13 (1): 197-205. 10.1183/09031936.99.14614549.CrossRefPubMed Janssens JP, Pache JC, Nicod LP: Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999, 13 (1): 197-205. 10.1183/09031936.99.14614549.CrossRefPubMed
6.
go back to reference Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al: Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008, 63 (12): 1046-1051. 10.1136/thx.2008.098483.CrossRefPubMed Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al: Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008, 63 (12): 1046-1051. 10.1136/thx.2008.098483.CrossRefPubMed
7.
go back to reference Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26 (5): 948-968. 10.1183/09031936.05.00035205.CrossRefPubMed Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26 (5): 948-968. 10.1183/09031936.05.00035205.CrossRefPubMed
8.
go back to reference Vaz Fragoso CA, Concato J, McAvay G, Van Ness PH, Rochester CL, Yaggi HK: The Ratio of Forced Expiratory Volume In 1-Second to Forced Vital Capacity as a Basis for Establishing Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2010, 181 (5): 446-451. 10.1164/rccm.200909-1366OC.CrossRefPubMed Vaz Fragoso CA, Concato J, McAvay G, Van Ness PH, Rochester CL, Yaggi HK: The Ratio of Forced Expiratory Volume In 1-Second to Forced Vital Capacity as a Basis for Establishing Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2010, 181 (5): 446-451. 10.1164/rccm.200909-1366OC.CrossRefPubMed
9.
go back to reference Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002, 20 (5): 1117-1122. 10.1183/09031936.02.00023202.CrossRefPubMed Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002, 20 (5): 1117-1122. 10.1183/09031936.02.00023202.CrossRefPubMed
10.
go back to reference Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, et al: FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest. 2006, 130 (1): 200-206. 10.1378/chest.130.1.200.CrossRefPubMed Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, et al: FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest. 2006, 130 (1): 200-206. 10.1378/chest.130.1.200.CrossRefPubMed
11.
go back to reference Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A, et al: COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007, 30 (2): 232-239. 10.1183/09031936.00157906.CrossRefPubMedPubMedCentral Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A, et al: COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007, 30 (2): 232-239. 10.1183/09031936.00157906.CrossRefPubMedPubMedCentral
12.
go back to reference Vollmer WM, Gislason T, Burney P, Enright PL, Gulsvik A, Kocabas A, et al: Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009, 34 (3): 588-597. 10.1183/09031936.00164608.CrossRefPubMedPubMedCentral Vollmer WM, Gislason T, Burney P, Enright PL, Gulsvik A, Kocabas A, et al: Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009, 34 (3): 588-597. 10.1183/09031936.00164608.CrossRefPubMedPubMedCentral
13.
go back to reference Medbo A, Melbye H: Lung function testing in the elderly-can we still use FEV1/FVC < 70% as a criterion of COPD?. Respir Med. 2007, 101 (6): 1097-1105. 10.1016/j.rmed.2006.11.019.CrossRefPubMed Medbo A, Melbye H: Lung function testing in the elderly-can we still use FEV1/FVC < 70% as a criterion of COPD?. Respir Med. 2007, 101 (6): 1097-1105. 10.1016/j.rmed.2006.11.019.CrossRefPubMed
14.
go back to reference Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL: Interpreting lung function data using 80 percent of predicted and fixed thresholds misclassifies over 20% of patients. Chest. 2011, 139 (1): 52-59. 10.1378/chest.10-0189.CrossRefPubMed Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL: Interpreting lung function data using 80 percent of predicted and fixed thresholds misclassifies over 20% of patients. Chest. 2011, 139 (1): 52-59. 10.1378/chest.10-0189.CrossRefPubMed
15.
go back to reference Hoogendoorn M, Feenstra TL, Schermer TRJ, Hesselink AE, Rutten-van Molken MPH: Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Resp Med. 2006, 100 (1): 83-86. 10.1016/j.rmed.2005.04.004.CrossRef Hoogendoorn M, Feenstra TL, Schermer TRJ, Hesselink AE, Rutten-van Molken MPH: Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Resp Med. 2006, 100 (1): 83-86. 10.1016/j.rmed.2005.04.004.CrossRef
16.
go back to reference Schermer TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, van Boxem TJ, et al: Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J. 2008, 32 (4): 945-952. 10.1183/09031936.00170307.CrossRefPubMed Schermer TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, van Boxem TJ, et al: Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J. 2008, 32 (4): 945-952. 10.1183/09031936.00170307.CrossRefPubMed
17.
go back to reference Mannino DM, Buist AS, Vollmer WM: Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax. 2007, 62 (3): 237-241. 10.1136/thx.2006.068379.CrossRefPubMed Mannino DM, Buist AS, Vollmer WM: Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax. 2007, 62 (3): 237-241. 10.1136/thx.2006.068379.CrossRefPubMed
18.
go back to reference Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, Anto JM, et al: Underestimation of airflow obstruction among young adults using FEV1/FVC < 70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax. 2008, 63 (12): 1040-1045. 10.1136/thx.2008.095554.CrossRefPubMed Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, Anto JM, et al: Underestimation of airflow obstruction among young adults using FEV1/FVC < 70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax. 2008, 63 (12): 1040-1045. 10.1136/thx.2008.095554.CrossRefPubMed
19.
go back to reference Mannino DM, Diaz-Guzman E: Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest. 2012, 141 (1): 73-80. 10.1378/chest.11-0797.CrossRefPubMed Mannino DM, Diaz-Guzman E: Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest. 2012, 141 (1): 73-80. 10.1378/chest.11-0797.CrossRefPubMed
20.
go back to reference Soriano JB, Zielinski J, Price D: Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009, 374 (9691): 721-732. 10.1016/S0140-6736(09)61290-3.CrossRefPubMed Soriano JB, Zielinski J, Price D: Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009, 374 (9691): 721-732. 10.1016/S0140-6736(09)61290-3.CrossRefPubMed
21.
go back to reference Enright P, Brusasco V: Counterpoint: Should We Abandon FEV1/FVC < 0.70 To Detect Airway Obstruction? Yes. Chest. 2010, 138 (5): 1040-1042. 10.1378/chest.10-2052.CrossRefPubMed Enright P, Brusasco V: Counterpoint: Should We Abandon FEV1/FVC < 0.70 To Detect Airway Obstruction? Yes. Chest. 2010, 138 (5): 1040-1042. 10.1378/chest.10-2052.CrossRefPubMed
22.
go back to reference Celli BR, Halbert RJ: Point: Should We Abandon FEV1/FVC < 0.70 To Detect Airway Obstruction? No. Chest. 2010, 138 (5): 1037-1040. 10.1378/chest.10-2049.CrossRefPubMed Celli BR, Halbert RJ: Point: Should We Abandon FEV1/FVC < 0.70 To Detect Airway Obstruction? No. Chest. 2010, 138 (5): 1037-1040. 10.1378/chest.10-2049.CrossRefPubMed
23.
go back to reference Robberts B, Schermer T: Abandoning FEV 1/FVC < 0.70 to detect airway obstruction. An essential debate, but with the right emphasis?. Chest. 2011, 139 (5): 1253-1254. 10.1378/chest.10-3099.CrossRefPubMed Robberts B, Schermer T: Abandoning FEV 1/FVC < 0.70 to detect airway obstruction. An essential debate, but with the right emphasis?. Chest. 2011, 139 (5): 1253-1254. 10.1378/chest.10-3099.CrossRefPubMed
24.
go back to reference Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-946. 10.1183/09031936.04.00014304.CrossRefPubMed Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-946. 10.1183/09031936.04.00014304.CrossRefPubMed
25.
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.CrossRefPubMed Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.CrossRefPubMed
26.
go back to reference Falaschetti E, Laiho J, Primatesta P, Purdon S: Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J. 2004, 23 (3): 456-463. 10.1183/09031936.04.00055204.CrossRefPubMed Falaschetti E, Laiho J, Primatesta P, Purdon S: Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J. 2004, 23 (3): 456-463. 10.1183/09031936.04.00055204.CrossRefPubMed
27.
go back to reference Brandli O, Schindler C, Leuenberger PH, Baur X, Degens P, Kunzli N, et al: Re-estimated equations for 5th percentiles of lung function variables. Thorax. 2000, 55 (2): 173-174.CrossRefPubMed Brandli O, Schindler C, Leuenberger PH, Baur X, Degens P, Kunzli N, et al: Re-estimated equations for 5th percentiles of lung function variables. Thorax. 2000, 55 (2): 173-174.CrossRefPubMed
28.
go back to reference Kuster SP, Kuster D, Schindler C, Rochat MK, Braun J, Held L, et al: Reference equations for lung function screening of healthy never-smoking adults aged 18-80 years. Eur Respir J. 2008, 31 (4): 860-868. 10.1183/09031936.00091407.CrossRefPubMed Kuster SP, Kuster D, Schindler C, Rochat MK, Braun J, Held L, et al: Reference equations for lung function screening of healthy never-smoking adults aged 18-80 years. Eur Respir J. 2008, 31 (4): 860-868. 10.1183/09031936.00091407.CrossRefPubMed
29.
go back to reference Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999, 159 (1): 179-187.CrossRefPubMed Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999, 159 (1): 179-187.CrossRefPubMed
30.
go back to reference Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31 (2): 416-469. 10.1183/09031936.00099306.CrossRefPubMed Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31 (2): 416-469. 10.1183/09031936.00099306.CrossRefPubMed
31.
go back to reference Hansen JE, Sun XG, Wasserman K: Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007, 131 (2): 349-355. 10.1378/chest.06-1349.CrossRefPubMed Hansen JE, Sun XG, Wasserman K: Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007, 131 (2): 349-355. 10.1378/chest.06-1349.CrossRefPubMed
32.
go back to reference Celli BR, Halbert RJ, Isonaka S, Schau B: Population impact of different definitions of airway obstruction. Eur Respir J. 2003, 22 (2): 268-273. 10.1183/09031936.03.00075102.CrossRefPubMed Celli BR, Halbert RJ, Isonaka S, Schau B: Population impact of different definitions of airway obstruction. Eur Respir J. 2003, 22 (2): 268-273. 10.1183/09031936.03.00075102.CrossRefPubMed
33.
go back to reference Albers M, Schermer T, Heijdra Y, Molema J, Akkermans R, Van WC: Predictive value of lung function below the normal range and respiratory symptoms for progression of chronic obstructive pulmonary disease. Thorax. 2008, 63 (3): 201-207. 10.1136/thx.2006.068007.CrossRefPubMed Albers M, Schermer T, Heijdra Y, Molema J, Akkermans R, Van WC: Predictive value of lung function below the normal range and respiratory symptoms for progression of chronic obstructive pulmonary disease. Thorax. 2008, 63 (3): 201-207. 10.1136/thx.2006.068007.CrossRefPubMed
34.
go back to reference Garcia-Rio F, Soriano JB, Miravitlles M, Munoz L, Duran-Tauleria E, Sanchez G, et al: Subjects "over-diagnosed" as COPD by the 0.7 fixed ratio have a poor health-related quality of life. Chest. 2011, 139 (5): 1072-1080. 10.1378/chest.10-1721.CrossRefPubMed Garcia-Rio F, Soriano JB, Miravitlles M, Munoz L, Duran-Tauleria E, Sanchez G, et al: Subjects "over-diagnosed" as COPD by the 0.7 fixed ratio have a poor health-related quality of life. Chest. 2011, 139 (5): 1072-1080. 10.1378/chest.10-1721.CrossRefPubMed
35.
go back to reference Bang KM, Gergen PJ, Kramer R, Cohen B: The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993, 103 (2): 536-540. 10.1378/chest.103.2.536.CrossRefPubMed Bang KM, Gergen PJ, Kramer R, Cohen B: The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993, 103 (2): 536-540. 10.1378/chest.103.2.536.CrossRefPubMed
Metadata
Title
Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects
Authors
Reinier P Akkermans
Marvin A Berrevoets
Ivo J Smeele
Annelies E Lucas
Bart P Thoonen
Joke G Grootens-Stekelenburg
Yvonne F Heijdra
Chris van Weel
Tjard R Schermer
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2012
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-12-12

Other articles of this Issue 1/2012

BMC Pulmonary Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.